TransCode Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for RNAZ, updated each market day.
RNAZ AI Sentiment
AI sees no strong directional signal for TransCode Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: May 1, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About TransCode Therapeutics, Inc. Common Stock
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
Sector
Exchange
Market Cap
$7,344,913
Cap Tier
Employees
12
Headquarters
BOSTON, MA
Listed Since
July 9, 2021
RNAZ Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
RNAZ Volatility
TransCode Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
